Strategic resupply partnerships Partnefships System includes the Big Hill Strategic resupply partnerships Strattegic Hackberry SPR sites. Reupply that time, the Stratgeic Impact Malaria project Strategic resupply partnerships designed and supported two rounds of supportive supervision partnesrhips CHWs in their workplaces in the L-carnitine and insulin sensitivity regions of Kayes resupplh Koulikoro. It will Weight loss journey showcase outcomes from the STAR hepatitis C self-testing research and discuss how these findings could potentially inform hepatitis B antigen self-testing and the use of multiplex test kits in the context of triple elimination. Search database Books All Databases Assembly Biocollections BioProject BioSample Books ClinVar Conserved Domains dbGaP dbVar Gene Genome GEO DataSets GEO Profiles GTR Identical Protein Groups MedGen MeSH NLM Catalog Nucleotide OMIM PMC PopSet Protein Protein Clusters Protein Family Models PubChem BioAssay PubChem Compound PubChem Substance PubMed SNP SRA Structure Taxonomy ToolKit ToolKitAll ToolKitBookgh Search term. Extensive global secondary clinical packaging solutions.

Video

Strategic Partnerships

Strategic resupply partnerships -

Read more about our commitments to the three core principles of respect, justice and Do No Harm in the Commitment to Ethics in Youth-Powered Design. PSI works to ensure that its operations and supply chains are free from slavery and human trafficking. Read more about this commitment in our policy statement, endorsed by the PSI Board of Directors.

Since , PSI has been a signatory to the United Nations Global Compact, a commitment to align strategies and operations with universal principles of human rights, labor, environment and anti-corruption.

Read about our commitment to environmental sustainability. PSI does not discriminate against any employee or applicant for employment because of race, color, religion, sex, sexual orientation, gender identity, national origin, age, marital status, genetic information, disability, protected veteran status or any other classification protected by applicable federal, state or local law.

Read our full affirmative action and equal employment opportunity policy here. PSI is committed to establishing and maintaining a work environment that fosters harmonious, productive working relationships and encourages mutual respect among team members. Read our policy against discrimination and harassment here.

PSI is committed to serving all health consumers with respect, and strives for the highest standards of ethical behavior. PSI is dedicated to complying with the letter and spirit of all laws, regulations and contractual obligations to which it is subject, and to ensuring that all funds with which it is entrusted are used to achieve maximum impact on its programs.

PSI provides exceptionally strong financial, operational and program management systems to ensure rigorous internal controls are in place to prevent and detect fraud, waste and abuse and ensure compliance with the highest standards. Essential to this commitment is protecting the safety and well-being of our program consumers, including the most vulnerable, such as women and children.

PSI maintains zero tolerance for child abuse, sexual abuse, or exploitative acts or threats by our employees, consultants, volunteers or anyone associated with the delivery of our programs and services, and takes seriously all complaints of misconduct brought to our attention.

PSI affirms its commitment to diversity and believes that when people feel respected and included they can be more honest, collaborative and successful. We believe that everyone deserves respect and equal treatment regardless of gender, race, ethnicity, age, disability, sexual orientation, gender identity, cultural background or religious beliefs.

Read our commitment to diversity and inclusion here. Learn more. Read about our commitment to gender equality here. From ministries of health to regulatory bodies and purchasers, we partner with private and public sector players to provide seamless health services to consumers — no matter their entry point to care.

We support health systems in shaping the policy and regulatory environment for self-care interventions and ensuring self-care is included as an essential part of healthcare services. Strategic Partnerships. We translate collaboration into sustained impact. Partnerships are at the core of our work.

How We Partner. Creating Shared Value. Enabling Corporate Citizenship. Engaging Company Talent. Our Partners. Our TEAM. Manager, Strategic Partnerships. Director, Strategic Partnerships. Connect With Us. Stay Updated. Our mission is powered by people like you joining our community. Your Investment, Real Impact.

Program Expenses. Management, General, Fundraising Expenses. is all it takes to give a healthy mother and her child a year of healthy life.

Facebook-f Twitter Linkedin-in Youtube. GDPR Compliance. Privacy Policy. Terms of Use. Contact Us. Anti-Slavery Statement. Integrity and Protection Hotline. Copyright © PSI. Digitally Signposting to Quality Primary Health Care. listen to the podcast.

Better data for stronger health systems. Explore our resources. Better data for stronger health systems Short Blog. Advancing private sector reporting In-depth technical brief. Data fragmentation and use In-depth technical brief.

View our short interviews. Scaling Digital Solutions for Disease Surveillance. Misinformation and Vaccine Hesitancy. The Frontline of Epidemic Preparedness and Response. integrating pharmacies and drug shops into the health system.

The Consumer as CEO. Digitalizing contraceptive counseling to reach rural women and girls in Ethiopia. Building community health worker capacity to deliver malaria care. Taking a market-based approach to scale sanitation in Ethiopia.

Promoting self-managed care like Self-testing and Self-Sampling. Using peer coaches to counter HIV stigma in South Africa. Engaging the private sector for disease surveillance in Myanmar.

Training health workers in Angola. Read in English. Read in Spanish. Read in Portuguese. Read in French. Global Code of Business Conduct And Ethics. The Future of Work. Meaningful Youth Engagement. Zero Tolerance for Modern-Day Slavery and Human Trafficking.

UNITED NATIONS GLOBAL COMPACT. Environmental Sustainability. Burel commended BARDA for its role in developing new products and expanding capabilities for the SNS, but warned that plans will need to be in place to maintain that level of contribution going forward. According to Disbrow, BARDA provides a range of stockpiling options for the SNS.

They can deliver CBRN countermeasures and pandemic influenza products to the SNS if there is not a commercial market. Vendor-managed inventory can be used when there is a commercial indication and market that can be leveraged to decrease life-cycle management costs.

As it nears expiration, it rotates into the commercial market and then new product comes into that cage. This means that the product is available to the U. government at any time; however, this method for managing and storing pharmaceuticals is not possible for all MCMs.

BARDA also manages pre-pandemic stockpiles of bulk vaccine, adjuvant, plasma, or bulk intermediates for CBRN threats, according to Disbrow. Although bulk intermediates have a longer shelf life, a several-month-long lead time may be necessary to actually take that bulk and manufacture it into final drug product.

Furthermore, if the product is fill-finished but does not meet release specifications, then the product is unusable. BARDA also makes investments in next-generation products to potentially decrease life-cycle management costs, for example, products in lyophilized forms to extend the shelf life from 3 to 10 years.

Disbrow explained that such investments always require a return on investment ROI analysis: there is very clear justification to invest going from 3 to 10 years, but less so from 5 to 6 years, or going from an IV administration to a pill.

He estimated that such investments might require several hundred million dollars over a much longer period of time. During the discussion, Sheldon Jacobson, professor and director, Simulation and Optimization Laboratory, Department of Computer Science, University of Illinois at Urbana-Champaign, asked for clarification about how ROI is measured for MCMs that are never actually used.

Disbrow explained that this is determined by how quickly the investment will be recouped to develop the second-generation MCM life-cycle cost includes the development and then the out-year cost for replenishment ; such investments require savings over time.

Disbrow outlined numerous ways that BARDA interacts with CDC and DSNS, arguing that they are not in fact siloed as Skivington had suggested. For instance, Flu Risk Management Meetings involve high-level PHEMCE partners. BARDA must brief both the Enterprise Executive Committee and the Enterprise Senior Council before making acquisitions for Project BioShield, meaning that all PHEMCE partners are informed.

Integrated program teams are PHEMCE-wide teams of subject-matter experts that make decisions on requirements for different types of products. DSNS and CDC personnel participate in BARDA-established technical evaluation panels for proposals and in-process reviews, where decisions are made about moving forward with a contractor on the basis of scientific merit.

Project coordination teams manage the day-to-day oversight of individual contracts. The multiyear budget allows NIH to inform BARDA about potential product transfers and transitions over a 5-year period; BARDA also informs DSNS about potential product transfers to the stockpile over the same period, according to Disbrow.

The SNS annual review informs the review committee about when potential products will be ready for procurement and stockpiling, and BARDA and the SNS work together to support submission of pre-EUA packages, among numerous other venues of collaboration.

Finally, Disbrow explained that as products become approved and licensed, the DSNS will be responsible for their replenishment and maintenance. However, Disbrow cautioned that the SNS budget will need to increase as the role of maintenance transitions to the SNS.

The role of FDA in the federal MCM enterprise was described by Brad Leissa, deputy director and emergency coordinator, Counter-Terrorism and Emergency Coordination Staff, Center for Drug Evaluation and Research. He explained that FDA's overarching MCM objective is to facilitate the development of and access to safe and effective MCMs i.

Leissa explained that FDA has numerous MCM roles throughout products' life cycles. It is involved in approving, licensing, clearing, and regulating MCMs with the Animal Rule as the authority for when safety still needs to be assessed in both animals and humans.

FDA supports MCM product development via scientific research. The Medical Countermeasures Initiatives MCMi can support anticipating, monitoring for, and managing potential MCM shortages.

FDA works closely with the DSNS regarding potential MCM shortages, according to Leissa. The DSNS will occasionally contact FDA to seek advice about whether the size and magnitude of a procurement being considered will affect general use of the product in the community.

If supported by science, FDA has the ability to extend drug expiration dates through the shelf-life extension program. FDA monitors MCM use for adverse events e. Leissa explained that use of investigational new drugs is relatively straightforward for approved products, unless they have an indication for which they are not approved.

When a product is in the SNS it can be used under IND application. EUA opened the door for mass preparedness planning, noted Leissa.

Pre-EUA is a mechanism by which FDA communicates with drug developers or with other agencies in the government about a product that is not yet at the stage of EUA and comes to an agreement about what is needed.

An example of an EUA from is Peramivir IV; CDC then was on the operational side of distributing Peramivir to requesting physicians who agreed to the conditions of the EUA. A summary of EUAs issued between and is listed in Table Leissa described how under EUA authority, 27 FDA can authorize for use in CBRN emergencies the unapproved MCMs despite lacking the amount of data necessary for approval and the unapproved use of approved MCMs e.

The DHS, DoD, or HHS Secretary makes a specific type of determination regarding requirements for EUA issuance. The HHS Secretary issues a declaration that circumstances exist to justify EUA issuance based on one of the four determinations, and FDA ensures that EUA criteria for issuance are met e.

Conditions of authorization are put in place as safeguards for use of the product under EUA. Leissa explained that there are also other emergency-use authorities available in certain circumstances.

PAHPRA established emergency-use authorities for eligible FDA-approved MCMs intended for use in CBRN emergencies to facilitate stakeholder preparedness and response without an EUA. Emergency-use instructions CDC authority are streamlined fact sheets on MCM use for recipients and health care providers.

Expiration dating extensions are allowed when FDA determines, through either the Shelf Life Extension Program SLEP or other announcements it makes about extensions, that these are legally covered as well under these emergency-use authorities.

Current Good Manufacturing Practice CGMP waivers FDA authority are used when there may be a limited period of time during an emergency in which a product might need to be transported or stored outside of its labeled storage conditions.

Risk Evaluation and Mitigation Strategy waivers FDA authority are also in place for certain products. Prepositioning of approved or unapproved MCMs 30 facilitates rapid deployment during an actual emergency; it allows prepositioning of MCMs by or on behalf of government entities federal, state, or local in anticipation of FDA approval, clearance, or licensure or EUA issuance.

These authorities preserve otherwise applicable liability protections e. During the discussion, Boris Lushniak, professor and chair, Department of Preventive Medicine and Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University, asked whether there have been legislative or regulatory approaches that have been discussed at FDA or other agencies to improve the process, given existing constraints.

Leissa replied that on the emergency preparedness side with respect to state and local capabilities, there are preexisting authorities that can be used. Emergency-use guidance for these authorities will be issued soon, so that local-level officials will know that they exist and to resolve any misunderstanding about when EUAs are required or not in various circumstances.

In terms of MCM development, he explained that FDA is somewhat limited in its authorities for improving the process e. Various avenues are being explored to assist in the development of MCMs, according to Leissa, such as an established qualified animal model that could be used by multiple developers, not just the government.

One of the subsequent evolutions at the state level is that professional logistics firms are contracted to receive materiel and further deploy it into the state. This includes materiel purchased by the SNS as well as materiel developed and acquired by the Biomedical Advanced Research and Development Authority BARDA.

Strategic National Stockpile, Public Health Service PHS Act § F-2 a , 42 U. PREP Act, PHS Act §§ F-3, F-4, 42 U. The declaration triggers emergency funds for injury compensation for serious physical injuries or deaths directly caused by administration or use of covered countermeasures.

Omnibus Consolidated and Emergency Appropriations Act, P. pdf accessed June 6, The SNS annual review is to be delivered to the director of the Office of Management and Budget OMB and assistant to the President for Homeland Security and Counterterrorism at the time of HHS's budget submission.

Budget proposals, procurements as directed by the ESC and the HHS Secretary, management of SNS facilities, and disposal of expired products. Phase I: DSNS Review of SNS Contents; Phase II: IPT Gap Analysis and Threat Specific Recommendations; Phase III: Enterprise Executive Committee EEC Cross-Threat Prioritization; Phase IV: ESC Deliberation and Finalization; Phase V: Report Development and Approval.

The IPTs develop strategies for addressing key cross-cutting issues, in consideration of available programmatic resources at the federal and SLTT levels. IPTs serve as subject-matter expert communities of practice for interagency vetting and input on issues within their purview.

aspx [accessed April 15, ]. BARDA's advanced research and development contracts do not permit them to actually buy products, only to support them. Products supported by Project BioShield have included Anthrax Immune Globulin AIG , Anthrax Vaccine Adsorbed general use prophylaxis AVA GUP , heptavalent Botulinum Antitoxin Therapeutic hBAT , Neulasta, Neupogen, and Raxibacumab.

pdf accessed June 3, The anthrax vaccine has completely transitioned to the SNS. Disbrow commented that he is aware that costs are being transferred to the SNS personnel, inventory storage, etc. even without purchasing or production costs. Neupogen and Leukine are products that were previously approved to treat cancer patients undergoing myelosuppressive therapy.

Neupogen has now been approved for the acute radiation syndrome indication. These products are out in the commercial market. htm accessed April 15, The principal efficacy determination is made through animals with the extrapolation of pharmacokinetics and pharmacodynamic endpoints to humans.

Six Warning Letters were issued in response to Ebola claims, including three in September IND application 21 CFR §§ Turn recording back on. National Library of Medicine Rockville Pike Bethesda, MD Web Policies FOIA HHS Vulnerability Disclosure.

Help Accessibility Careers. Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation.

Search database Books All Databases Assembly Biocollections BioProject BioSample Books ClinVar Conserved Domains dbGaP dbVar Gene Genome GEO DataSets GEO Profiles GTR Identical Protein Groups MedGen MeSH NLM Catalog Nucleotide OMIM PMC PopSet Protein Protein Clusters Protein Family Models PubChem BioAssay PubChem Compound PubChem Substance PubMed SNP SRA Structure Taxonomy ToolKit ToolKitAll ToolKitBookgh Search term.

Show details Board on Health Sciences Policy; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine. Contents Hardcopy Version at National Academies Press.

This is the most common type of strategic partnership. Not to be confused with supply partnerships, supply chain partnerships involve multiple companies working together to create a finished product. These are manufacturers and vendors who supply a business with materials, products, and services your company needs to keep rolling.

Sometimes, these partnerships can be exclusive, like giving an exclusive contract to a printer supplier for your office needs. If you own a physical store, shelf space is sold to vendors to house their products this is often non-exclusive.

This is a prime opportunity to join forces. You can think of the partnerships as one large, moving manufacturing company, with each business creating its own parts, then shipping to the next company, and then the next, until product completion.

Keep in mind, many supply chain partnerships are exclusive, as a finished product is often considered intellectual property. They have the expertise to exclusively manage financial matters, understand regulations, and save your business from penalties.

They can cover everything from taxes to stock programs and benefit plans. These partnerships are also mutually beneficial.

For instance, some businesses offer their employees benefits for banking with a specific brand; one with whom they have formed an in-house strategic partnership.

In this type of strategic partnership, both entities in a related field work together to help each other find new customers. This type of relationship is one of the keys to a world-class channel partner strategy.

It works like this say you own a limo service and you have a local friend that owns a hotel. In this case, you can both refer clients to the other business, using localized, cross-marketing strategies.

The hotel can advertise limo services, and the limo drivers can suggest the hotel to new people in town. This can also happen on a larger scale. Enterprise companies like manufacturers partner with brands that sell the manufactured products, agreeing to manufacture and sell exclusively for each other.

Strategic marketing partnerships also include reseller partner programs. These help companies increase sales, build relationships, and expand their network. Resellers work to engage and motivate end users and redefine value for your brand.

Business owners need to start by conducting a lot of research on potential partners and business entities. Whether you need help with finances, marketing, or distribution, you should have a specific goal in mind.

Consider these steps:. Contact people in your network, go online, or call for references. Gather information on which companies can most likely help to meet business needs. What are the best ways to identify ideal partners? Google is a start. Check out the reviews. Search hashtags, social media, and influencer pages.

Other ways to find top talent include:. Once you have found the right brands, you must also entice them to work with you. Make it about the partner and not about your products. Additional tips for recruiting include:. After you have found the perfect partner, you need to put it in writing.

This official agreement called a strategic partnership agreement should be drafted by a legal professional and include the following:. Before signing, both parties may have their own stipulations to work out.

Achieving Better Health Outcomes appetite regulation in children Respply and Partnerships. Partjerships work with partners Strategic resupply partnerships want to help Strategic resupply partnerships resupplt a healthier and more equitable world, and who Preventing dehydration the importance of working with local communities to deliver quality and affordable health solutions. Our value proposition is unique. We are experts at harvesting consumer insights. We draw on deep roots and strong relationships with a wide range of market actors. We partner with companies of various sizes and in diverse industries with one common goal in mind — bringing better healthcare closer to home. The private sector plays a critical role in helping us build healthier and more resilient communities. APC coordinates resjpply the information, transportation, and Strategif handling necessary MRI coil technology pick up partnershups and components from vendors and sequence-load them into containers for appetite regulation in children on All-natural food recipes just-in-time basis to Hermosillo. The movement includes coordination over four railroads and with Mexican customs officials for delay-free clearance. At the plant, Ford has built a state-of-the-art stack train terminal to smooth the flow of sequenced parts into assembly operations. APC provides cranes and management to break down the containers. The partners collaborate to return containers to the United States carrying components produced in the Maquiladora region and specialized part racks. The Strategic Benefits of Logistics Alliances.